%0 Journal Article %1 Mastellos:2017cga %A Mastellos, Dimitrios C %A Reis, Edimara S %A Ricklin, Daniel %A Smith, Richard J %A Lambris, John D. %D 2017 %J Trends in Immunology %K imported %N 6 %P 383--394 %R 10.1016/j.it.2017.03.003 %T Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. %U http://linkinghub.elsevier.com/retrieve/pii/S1471490617300534 %V 38 %X Complement dysregulation underlies several inflammatory disorders, and terminal complement inhibition has thus far afforded significant clinical gains. Nonetheless, emerging pathologies, fueled by complement imbalance and therapy-skewing genetic variance, underscore the need for more comprehensive, disease-tailored interventions. Modulation at the level of C3, a multifaceted orchestrator of the complement cascade, opens up prospects for broader therapeutic efficacy by targeting multiple pathogenic pathways modulated by C3-triggered proinflammatory crosstalk. Notably, C3 intervention is emerging as a viable therapeutic strategy for renal disorders with predominantly complement-driven etiology, such as C3 glomerulopathy (C3G). Using C3G as a paradigm, we argue that concerns about the feasibility of long-term C3 intervention need to be placed into perspective and weighed against actual therapeutic outcomes in prospective clinical trials.

@article{Mastellos:2017cga, abstract = {Complement dysregulation underlies several inflammatory disorders, and terminal complement inhibition has thus far afforded significant clinical gains. Nonetheless, emerging pathologies, fueled by complement imbalance and therapy-skewing genetic variance, underscore the need for more comprehensive, disease-tailored interventions. Modulation at the level of C3, a multifaceted orchestrator of the complement cascade, opens up prospects for broader therapeutic efficacy by targeting multiple pathogenic pathways modulated by C3-triggered proinflammatory crosstalk. Notably, C3 intervention is emerging as a viable therapeutic strategy for renal disorders with predominantly complement-driven etiology, such as C3 glomerulopathy (C3G). Using C3G as a paradigm, we argue that concerns about the feasibility of long-term C3 intervention need to be placed into perspective and weighed against actual therapeutic outcomes in prospective clinical trials.}, added-at = {2017-12-08T05:18:19.000+0100}, affiliation = {Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Division of Biodiagnostic Sciences and Technologies, Institute of Nuclear and Radiological Sciences and Technology, Energy, and Safety (INRASTES), National Center for Scientific Research 'Demokritos', Aghia Paraskevi Attikis, 15310 Athens, Greece.}, author = {Mastellos, Dimitrios C and Reis, Edimara S and Ricklin, Daniel and Smith, Richard J and Lambris, John D.}, biburl = {https://www.bibsonomy.org/bibtex/298a8c3c1b761e9bac1f91fe5f4d6bd64/lambris}, date-added = {2017-12-08T04:15:39GMT}, date-modified = {2017-12-08T04:17:38GMT}, doi = {10.1016/j.it.2017.03.003}, interhash = {4ee26fa6d40d0f817aaf547d9ac19536}, intrahash = {98a8c3c1b761e9bac1f91fe5f4d6bd64}, journal = {Trends in Immunology}, keywords = {imported}, language = {English}, month = jun, number = 6, pages = {383--394}, pmcid = {PMC5447467}, pmid = {28416449}, rating = {0}, timestamp = {2017-12-08T05:18:19.000+0100}, title = {{Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.}}, uri = {\url{papers3://publication/doi/10.1016/j.it.2017.03.003}}, url = {http://linkinghub.elsevier.com/retrieve/pii/S1471490617300534}, volume = 38, year = 2017 }